Pay Me Now & Pay Me Later: The “Whole Person” Approach To Alzheimer’s Treatment

June is Alzheimer’s and Brain Awareness Month—and there is much to think about. The world is abuzz with the approval of Aduhelm—the first new drug for Alzheimer’s treatment since 2003 (see FDA Approves Biogen’s Aduhelm, A New Treatment For Alzheimer’s Disease). This comes at a time when projections of the future prevalence and cost of Alzheimer’s disease continue to mount. The latest Health and Retirement Study (HRS) from the University of Michigan (see Aging In The 21st Century) estimates that there are currently 5.1 million consumers over 65 years old with Alzheimer . . .